Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Future directions for CLDN18.2-specific CAR T-cell therapy in GI cancers

Gregory P. Botta • 13 Jun 2022
ASCO 2022
Gastrointestinal Cancer CAR-T

Gregory P. Botta, MD, PhD, UC San Diego Medical Center, San Diego, CA, discusses the next steps for CLDN18.2-specific CAR T-cell therapy in GI cancers. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Gregory P. Botta

2:01
Salvage CT041 CLDN18.2-specific CAR T-cell therapy for patients with advanced GI malignancies
Gregory P. Botta • 13 Jun 2022
0:34
Expanding indications for a CLDN18.2-specific CAR T-cell therapy in GI cancers
Gregory P. Botta • 13 Jun 2022
2:16
Safety and efficacy of a CLDN18.2-specific CAR T-cell therapy in GI adenocarcinoma
Gregory P. Botta • 13 Jun 2022

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals